Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04876638 · ClinicalTrials.gov registry record · Phase 2
Minocycline for Aneurysmal Subarachnoid Hemorrhage (MASH)
A Phase 2 study of Delayed Cerebral Ischemia and Vasospasm, Intracranial, sponsored by University of Southern California.
- Active
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04876638 is a Phase 2 study of Delayed Cerebral Ischemia and Vasospasm, Intracranial that is active but no longer recruiting, run by University of Southern California. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04876638, a Phase 2 study of Delayed Cerebral Ischemia and Vasospasm, Intracranial, is active but no longer recruiting, sponsored by University of Southern California.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Previous work has demonstrated patients presenting with ruptured aneurysms that develop radiographic and clinical vasospasm have a higher permeability of the blood brain membrane. Matrix metalloproteinase 9 (MMP9) has been studied and recently implicated in both the pathogenesis of the blood brain barrier breakdown and vasogenic edema of ischemia strokes, and is suggested to be an accurate biomarker to predict the onset of cerebral vasospasm after subarachnoid hemorrhage. The therapeutic benefit of minocycline, an MMP9 inhibitor, has been investigated in ischemic stroke population, however its role in the treatment of cerebral vasospasm from ruptured aneurysms remains unknown. Our project has two main goals: to further confirm MMP9 has a reliable biomarker for the onset of cerebral vasospasm, and secondarily to investigate any possible therapeutic benefit that minocycline has in the vasospasm population. Vasospasm continues to be one of the major contributors of morbidity and mortality in the ruptured aneurysm population, and close monitoring of the neurologic exam during the 'vasospasm window' usually requires two weeks in the intensive care unit in most academic settings. As such, if we are better able to predict which patients are at risk of developing vasospasm based on MMP9 levels, we will be better able to anticipate the need for intervention and therefore mitigate the risk of vasospasm induced ischemic strokes, ultimately resulting in better outcomes in the ruptured aneurysm population. Further, if we are able to identify minocycline as a therapeutic agent to deter, or lessen the severity of vasospasm, we can possibly improve neurologic outcomes, decrease hospital stays, ultimately providing an improved and more cost-effective treatment strategy to our patients.
Conditions Studied
Interventions
- DRUG Minocyclin
Study Locations (1)
California
- University of Southern California Department of Neurosurgery - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04876638
The ClinicalTrials.gov registry entry for NCT04876638 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Delayed Cerebral Ischemia appearing as the primary indexed condition, and to 1 intervention - of which Minocyclin is the first listed.
NCT04876638 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04876638 about?
NCT04876638 is a clinical study titled "Minocycline for Aneurysmal Subarachnoid Hemorrhage (MASH)". Previous work has demonstrated patients presenting with ruptured aneurysms that develop radiographic and clinical vasospasm have a higher permeability of the blood brain membrane. Matrix metalloproteinase 9 (MMP9) has been studied and recently implicated in both the pathogenesis of the blood brain b...
What is the current status of trial NCT04876638?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-07-01. Estimated completion is 2028-12-30.
What conditions does trial NCT04876638 study?
This clinical trial studies the following conditions: Delayed Cerebral Ischemia, Vasospasm, Intracranial, Aneurysm, Ruptured, Blood Brain Barrier Defect.
What interventions are being tested in trial NCT04876638?
The interventions under investigation include: Minocyclin (DRUG).
Who is sponsoring clinical trial NCT04876638?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04876638 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Delayed Cerebral Ischemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.